Dror Shir, Noah Lee, Stuart J McCarter, Vijay K Ramanan, Hugo Botha, David S Knopman, Ronald C Petersen, Bradley F Boeve, Gregory Scott Day, Neill R Graff-Radford, David T Jones, Melissa E Murray, Aivi T Nguyen, R Ross Reichard, Dennis W Dickson, Deena Tajfirouz, Mary M Machulda, Jennifer L Whitwell, Keith Anthony Josephs, Jonathan Graff-Radford
{"title":"Longitudinal Evolution of Posterior Cortical Atrophy: Diagnostic Delays, Overlapping Phenotypes, and Clinical Outcomes.","authors":"Dror Shir, Noah Lee, Stuart J McCarter, Vijay K Ramanan, Hugo Botha, David S Knopman, Ronald C Petersen, Bradley F Boeve, Gregory Scott Day, Neill R Graff-Radford, David T Jones, Melissa E Murray, Aivi T Nguyen, R Ross Reichard, Dennis W Dickson, Deena Tajfirouz, Mary M Machulda, Jennifer L Whitwell, Keith Anthony Josephs, Jonathan Graff-Radford","doi":"10.1212/WNL.0000000000213559","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Although several large studies have evaluated individuals with posterior cortical atrophy (PCA) cross-sectionally, its longitudinal progression remains poorly characterized. The objectives of this study were to determine the longitudinal trajectory of PCA, encompassing the temporal aspects of diagnosis, the spectrum of clinical manifestations, and patient outcomes.</p><p><strong>Methods: </strong>This retrospective study included participants evaluated and diagnosed with PCA at the Mayo Clinic, between 1995 and 2023. Clinical data (demographics, neurologic evaluations, and cognitive tests at initial presentation and late stage) were extracted from medical records. Initial clinical diagnoses during previous medical evaluations, including ophthalmologic assessments after onset of neurologic symptoms, were documented. Participants were retrospectively classified as PCA-pure if they solely met PCA criteria or as PCA-plus if they exhibited complex phenotypes also meeting criteria for other neurodegenerative syndromes. CSF analyses and neuropathology findings were documented.</p><p><strong>Results: </strong>The cohort of 558 participants (65% female) had a mean age at symptom onset of 61 ± 8 years, with 68% meeting early-onset criteria (younger than 65 years). The mean duration from symptom onset to diagnosis was 3.6 ± 2.5 years. Ophthalmologic/optometric evaluations (49%) and completion of ophthalmologic procedures (16%) were common before PCA diagnosis. Psychiatric diagnoses were made in 23% of participants before PCA diagnosis, particularly among younger women. Common initial symptoms included misplacement of items, difficulties with reading and driving, and concerns pertaining to basic visual processing. Notable signs were constructional apraxia, dyscalculia, simultanagnosia, and space perception deficits. CSF biomarkers were consistent with Alzheimer disease in 139 of 158 individuals (88%). Superimposed features of non-PCA clinical syndromes were observed in a quarter of the participants at presentation, with frequency of PCA-plus cases increasing longitudinally. Longitudinal analysis of Short Test of Mental Status scores predicted an initial rapid decline in cognitive function, with the rate of decline gradually slowing over 0-10 years (time coefficient [SE] = -4.20 [0.29], <i>p</i> < 0.001).</p><p><strong>Discussion: </strong>This study highlights the protracted time from symptom onset and frequent misdiagnoses/misattribution of symptoms in PCA. Ophthalmologic evaluations often preceded neurologic assessments. Psychiatric diagnoses were more frequent among younger women. These observations highlight the need to improve diagnostic processes and earlier recognition of PCA, which may enhance the effectiveness of emerging disease-modifying therapies.</p>","PeriodicalId":19256,"journal":{"name":"Neurology","volume":"104 9","pages":"e213559"},"PeriodicalIF":7.7000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984831/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/WNL.0000000000213559","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Although several large studies have evaluated individuals with posterior cortical atrophy (PCA) cross-sectionally, its longitudinal progression remains poorly characterized. The objectives of this study were to determine the longitudinal trajectory of PCA, encompassing the temporal aspects of diagnosis, the spectrum of clinical manifestations, and patient outcomes.
Methods: This retrospective study included participants evaluated and diagnosed with PCA at the Mayo Clinic, between 1995 and 2023. Clinical data (demographics, neurologic evaluations, and cognitive tests at initial presentation and late stage) were extracted from medical records. Initial clinical diagnoses during previous medical evaluations, including ophthalmologic assessments after onset of neurologic symptoms, were documented. Participants were retrospectively classified as PCA-pure if they solely met PCA criteria or as PCA-plus if they exhibited complex phenotypes also meeting criteria for other neurodegenerative syndromes. CSF analyses and neuropathology findings were documented.
Results: The cohort of 558 participants (65% female) had a mean age at symptom onset of 61 ± 8 years, with 68% meeting early-onset criteria (younger than 65 years). The mean duration from symptom onset to diagnosis was 3.6 ± 2.5 years. Ophthalmologic/optometric evaluations (49%) and completion of ophthalmologic procedures (16%) were common before PCA diagnosis. Psychiatric diagnoses were made in 23% of participants before PCA diagnosis, particularly among younger women. Common initial symptoms included misplacement of items, difficulties with reading and driving, and concerns pertaining to basic visual processing. Notable signs were constructional apraxia, dyscalculia, simultanagnosia, and space perception deficits. CSF biomarkers were consistent with Alzheimer disease in 139 of 158 individuals (88%). Superimposed features of non-PCA clinical syndromes were observed in a quarter of the participants at presentation, with frequency of PCA-plus cases increasing longitudinally. Longitudinal analysis of Short Test of Mental Status scores predicted an initial rapid decline in cognitive function, with the rate of decline gradually slowing over 0-10 years (time coefficient [SE] = -4.20 [0.29], p < 0.001).
Discussion: This study highlights the protracted time from symptom onset and frequent misdiagnoses/misattribution of symptoms in PCA. Ophthalmologic evaluations often preceded neurologic assessments. Psychiatric diagnoses were more frequent among younger women. These observations highlight the need to improve diagnostic processes and earlier recognition of PCA, which may enhance the effectiveness of emerging disease-modifying therapies.
背景和目的:尽管有几项大型研究对后皮质萎缩(PCA)患者进行了横断面评估,但其纵向进展特征仍然很差。本研究的目的是确定PCA的纵向轨迹,包括诊断的时间方面,临床表现谱和患者结果。方法:这项回顾性研究纳入了1995年至2023年间在梅奥诊所评估和诊断为PCA的参与者。从医疗记录中提取临床数据(人口统计学、神经学评估和初诊和晚期的认知测试)。在先前的医学评估中,包括神经系统症状发作后的眼科评估,记录了初步临床诊断。如果参与者仅仅满足PCA标准,则回顾性地将其分类为PCA纯型,如果他们表现出复杂的表型并满足其他神经退行性综合征的标准,则将其分类为PCA加型。记录脑脊液分析和神经病理学结果。结果:558名参与者(65%为女性)的队列在症状发作时的平均年龄为61±8岁,68%符合早发标准(小于65岁)。从症状出现到诊断的平均时间为3.6±2.5年。在PCA诊断前,眼科/验光评估(49%)和完成眼科手术(16%)是常见的。23%的参与者在PCA诊断前进行了精神诊断,尤其是年轻女性。常见的初始症状包括物品放错位置,阅读和驾驶困难,以及与基本视觉处理有关的问题。值得注意的症状是结构性失用症、计算障碍、同时失认症和空间知觉缺陷。158人中有139人(88%)的脑脊液生物标志物与阿尔茨海默病一致。在四分之一的参与者中观察到非pca临床综合征的叠加特征,pca +病例的频率呈纵向增加。心理状态短测验(Short Test of Mental Status)的纵向分析预测认知功能在开始阶段快速下降,在0 ~ 10年内下降速度逐渐减慢(时间系数[SE] = -4.20 [0.29], p < 0.001)。讨论:本研究强调了PCA的症状出现时间较长和频繁的误诊/错误归因。眼科检查通常先于神经系统检查。精神疾病诊断在年轻女性中更为常见。这些观察结果强调了改进诊断过程和早期识别PCA的必要性,这可能会提高新兴疾病改善疗法的有效性。
期刊介绍:
Neurology, the official journal of the American Academy of Neurology, aspires to be the premier peer-reviewed journal for clinical neurology research. Its mission is to publish exceptional peer-reviewed original research articles, editorials, and reviews to improve patient care, education, clinical research, and professionalism in neurology.
As the leading clinical neurology journal worldwide, Neurology targets physicians specializing in nervous system diseases and conditions. It aims to advance the field by presenting new basic and clinical research that influences neurological practice. The journal is a leading source of cutting-edge, peer-reviewed information for the neurology community worldwide. Editorial content includes Research, Clinical/Scientific Notes, Views, Historical Neurology, NeuroImages, Humanities, Letters, and position papers from the American Academy of Neurology. The online version is considered the definitive version, encompassing all available content.
Neurology is indexed in prestigious databases such as MEDLINE/PubMed, Embase, Scopus, Biological Abstracts®, PsycINFO®, Current Contents®, Web of Science®, CrossRef, and Google Scholar.